Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 27, 2009

View Archived Issues

HSP 90 and kinase inhibitors presented by the University of Strasbourg

Novel TRPV1 receptor antagonists claimed by Renovis and Pfizer

C5aR antagonist shows promise in murine models of Alzheimer's disease

P2X7 receptor blockade improves functional recovery after SCI

Carisbamate suppresses alcohol intake in rat model of alcoholism

Johnson & Johnson develops DGAT1 inhibitors for treating the metabolic syndrome

Gefitinib derivatives in development at Concert Pharmaceuticals

Ustav Organicke Chemie a Biochemie discloses novel apoptosis inhibitors

PharmacoFore introduces novel anesthetics

Natco Pharma claims novel HER (erbB) tyrosine kinase and VEGFR inhibitors

Alpha2B- and alpha2C-adrenoceptor agonists identified at Allergan

Vertex reports results from second quarter 2009

Protalix receives FDA fast track designation for prGCD for Gaucher's disease

BioAlliance presents preliminary pivotal phase III results with acyclovir Lauriad

Lurasidone demonstrates efficacy in schizophrenia

Acorda reports FDA Advisory Committee review date for Fampridine-SR

FDA accepts Labopharm's resubmission response for novel trazodone hydrochloride formulation

Hawaii Biotech initiates phase I clinical trial for dengue vaccine

ISTA reports preliminary phase III results for once-daily Xibrom 0.09%

Morria obtains clearance to conduct phase II MRX-6 study for contact dermatitis

Adolor introduces novel cannabinoid CB2 receptor ligands as analgesics

Profectus enters research collaboration with the PATH Malaria Vaccine Initiative

Taisho and Nissan discontinue development of NT-702 for spinal canal stenosis

NovaBiotics completes phase I clinical study of Novexatin for onychomycosis

Novel antiplatelet agents presented by Astellas as potential clinical candidates

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...